Research ExplorerPublicationsAdditional cytogenetic features determine outcome in patient...

Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia

Standard

Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia. / Loke, Justin; Labopin, Myriam; Craddock, Charles; Cornelissen, Jan J; Labussière-Wallet, Hélène; Wagner-Drouet, Eva Maria; Van Gorkom, Gwendolyn; Schaap, Nicolaas P M; Kröger, Nicolaus M; Veelken, Joan Hendrik; Rovira, Montserrat; Menard, Anne Lise; Bug, Gesine; Bazarbachi, Ali; Giebel, Sebastian; Brissot, Eolia; Nagler, Arnon; Esteve, Jordi; Mohty, Mohamad.

In: CANCER-AM CANCER SOC, Vol. 128, No. 15, 01.08.2022, p. 2922-2931.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Loke, J, Labopin, M, Craddock, C, Cornelissen, JJ, Labussière-Wallet, H, Wagner-Drouet, EM, Van Gorkom, G, Schaap, NPM, Kröger, NM, Veelken, JH, Rovira, M, Menard, AL, Bug, G, Bazarbachi, A, Giebel, S, Brissot, E, Nagler, A, Esteve, J & Mohty, M 2022, 'Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia', CANCER-AM CANCER SOC, vol. 128, no. 15, pp. 2922-2931. https://doi.org/10.1002/cncr.34268

APA

Loke, J., Labopin, M., Craddock, C., Cornelissen, J. J., Labussière-Wallet, H., Wagner-Drouet, E. M., Van Gorkom, G., Schaap, N. P. M., Kröger, N. M., Veelken, J. H., Rovira, M., Menard, A. L., Bug, G., Bazarbachi, A., Giebel, S., Brissot, E., Nagler, A., Esteve, J., & Mohty, M. (2022). Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia. CANCER-AM CANCER SOC, 128(15), 2922-2931. https://doi.org/10.1002/cncr.34268

Vancouver

Loke J, Labopin M, Craddock C, Cornelissen JJ, Labussière-Wallet H, Wagner-Drouet EM et al. Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia. CANCER-AM CANCER SOC. 2022 Aug 1;128(15):2922-2931. https://doi.org/10.1002/cncr.34268

Bibtex

@article{40d27a89f4a84911a24776da171a8741,
title = "Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia",
abstract = "BACKGROUND: The presence of TP53 mutations is associated with an unfavorable outcome in patients allografted for acute myeloid leukemia (AML), leading some to question the benefit of an allogeneic stem cell transplantation (allo-SCT) for this patient group, although this has not been studied in a large cohort.METHODS: A total of 780 patients with AML in first complete remission, with either intermediate- or adverse-risk cytogenetics, whose TP53 mutation status was reported, were included in this study from the European Society for Blood and Marrow Transplantation.RESULTS: Two-year overall survival (OS) was impaired in patients (n = 179) with evidence of a TP53 mutation at diagnosis (35.1%; 95% confidence interval [CI], 26.7-43.7) as compared to the cohort without (n = 601) (64%; 95% CI, 59.1-68.4; P = .001). In patients with mutant TP53 AML with no evidence of either chromosome 17p loss (17p-) and/or complex karyotype (CK) (n = 53, 29.6%), 2-year OS was 65.2% (95% CI, 48.4-77.6). This was not significantly different to patients without TP53 mutations. In patients with mutant TP53 AML with either 17p- and/or CK (n = 126, 70.4%), the OS was lower (24.6%; 95% CI, 16.2-34; P = .001).CONCLUSIONS: In summary, the adverse prognostic effect of TP53 mutations in AML following an allo-SCT is not evident in patients with neither co-occurring 17p- and/or CK, and these data inform decisions regarding allo-SCT in patients with TP53 mutant AML.",
keywords = "Chromosome Deletion, Cytogenetic Analysis, Cytogenetics, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute/diagnosis, Prognosis, Retrospective Studies, Transplantation, Homologous, Tumor Suppressor Protein p53/genetics",
author = "Justin Loke and Myriam Labopin and Charles Craddock and Cornelissen, {Jan J} and H{\'e}l{\`e}ne Labussi{\`e}re-Wallet and Wagner-Drouet, {Eva Maria} and {Van Gorkom}, Gwendolyn and Schaap, {Nicolaas P M} and Kr{\"o}ger, {Nicolaus M} and Veelken, {Joan Hendrik} and Montserrat Rovira and Menard, {Anne Lise} and Gesine Bug and Ali Bazarbachi and Sebastian Giebel and Eolia Brissot and Arnon Nagler and Jordi Esteve and Mohamad Mohty",
note = "{\textcopyright} 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.",
year = "2022",
month = aug,
day = "1",
doi = "10.1002/cncr.34268",
language = "English",
volume = "128",
pages = "2922--2931",
journal = "CANCER-AM CANCER SOC",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "15",

}

RIS

TY - JOUR

T1 - Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia

AU - Loke, Justin

AU - Labopin, Myriam

AU - Craddock, Charles

AU - Cornelissen, Jan J

AU - Labussière-Wallet, Hélène

AU - Wagner-Drouet, Eva Maria

AU - Van Gorkom, Gwendolyn

AU - Schaap, Nicolaas P M

AU - Kröger, Nicolaus M

AU - Veelken, Joan Hendrik

AU - Rovira, Montserrat

AU - Menard, Anne Lise

AU - Bug, Gesine

AU - Bazarbachi, Ali

AU - Giebel, Sebastian

AU - Brissot, Eolia

AU - Nagler, Arnon

AU - Esteve, Jordi

AU - Mohty, Mohamad

N1 - © 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.

PY - 2022/8/1

Y1 - 2022/8/1

N2 - BACKGROUND: The presence of TP53 mutations is associated with an unfavorable outcome in patients allografted for acute myeloid leukemia (AML), leading some to question the benefit of an allogeneic stem cell transplantation (allo-SCT) for this patient group, although this has not been studied in a large cohort.METHODS: A total of 780 patients with AML in first complete remission, with either intermediate- or adverse-risk cytogenetics, whose TP53 mutation status was reported, were included in this study from the European Society for Blood and Marrow Transplantation.RESULTS: Two-year overall survival (OS) was impaired in patients (n = 179) with evidence of a TP53 mutation at diagnosis (35.1%; 95% confidence interval [CI], 26.7-43.7) as compared to the cohort without (n = 601) (64%; 95% CI, 59.1-68.4; P = .001). In patients with mutant TP53 AML with no evidence of either chromosome 17p loss (17p-) and/or complex karyotype (CK) (n = 53, 29.6%), 2-year OS was 65.2% (95% CI, 48.4-77.6). This was not significantly different to patients without TP53 mutations. In patients with mutant TP53 AML with either 17p- and/or CK (n = 126, 70.4%), the OS was lower (24.6%; 95% CI, 16.2-34; P = .001).CONCLUSIONS: In summary, the adverse prognostic effect of TP53 mutations in AML following an allo-SCT is not evident in patients with neither co-occurring 17p- and/or CK, and these data inform decisions regarding allo-SCT in patients with TP53 mutant AML.

AB - BACKGROUND: The presence of TP53 mutations is associated with an unfavorable outcome in patients allografted for acute myeloid leukemia (AML), leading some to question the benefit of an allogeneic stem cell transplantation (allo-SCT) for this patient group, although this has not been studied in a large cohort.METHODS: A total of 780 patients with AML in first complete remission, with either intermediate- or adverse-risk cytogenetics, whose TP53 mutation status was reported, were included in this study from the European Society for Blood and Marrow Transplantation.RESULTS: Two-year overall survival (OS) was impaired in patients (n = 179) with evidence of a TP53 mutation at diagnosis (35.1%; 95% confidence interval [CI], 26.7-43.7) as compared to the cohort without (n = 601) (64%; 95% CI, 59.1-68.4; P = .001). In patients with mutant TP53 AML with no evidence of either chromosome 17p loss (17p-) and/or complex karyotype (CK) (n = 53, 29.6%), 2-year OS was 65.2% (95% CI, 48.4-77.6). This was not significantly different to patients without TP53 mutations. In patients with mutant TP53 AML with either 17p- and/or CK (n = 126, 70.4%), the OS was lower (24.6%; 95% CI, 16.2-34; P = .001).CONCLUSIONS: In summary, the adverse prognostic effect of TP53 mutations in AML following an allo-SCT is not evident in patients with neither co-occurring 17p- and/or CK, and these data inform decisions regarding allo-SCT in patients with TP53 mutant AML.

KW - Chromosome Deletion

KW - Cytogenetic Analysis

KW - Cytogenetics

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Leukemia, Myeloid, Acute/diagnosis

KW - Prognosis

KW - Retrospective Studies

KW - Transplantation, Homologous

KW - Tumor Suppressor Protein p53/genetics

U2 - 10.1002/cncr.34268

DO - 10.1002/cncr.34268

M3 - SCORING: Journal article

C2 - 35612815

VL - 128

SP - 2922

EP - 2931

JO - CANCER-AM CANCER SOC

JF - CANCER-AM CANCER SOC

SN - 0008-543X

IS - 15

ER -